Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies

Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types.
This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a recommended Phase 2 dose (RP2D) for future studies.
Patients are currently being recruited for Part 3 of the study.
Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.